Clinical Trials | May 20, 2022
Motilal Oswal Private Equity (MOPE) invests in Pathkind Diagnostics
A primary investment of Rs 194.4 crore has been made
A primary investment of Rs 194.4 crore has been made
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Pharmapack Europe recognizes excellence and innovation from exhibitors across connected devices, sustainability, supply chain logistics, route of administration, and packaging innovation, as well from the wider industry for patient-centric design and eco-design
This cost-effective tool will be of immense benefit to other high burden countries as well.
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
As part of large-scale clinical studies prior to market introduction, the AI software has now gone into clinical test with patients, so-called first-in-human applications
The curriculum has been curated for General Physicians working in Clinikk
This new fund is amongst the largest for the sector in India
Union Minister of State for Science and Technology, Dr Jitendra Singh gave the award for the successful commercialization of indigenous technology on National Technology Day 2022
Subscribe To Our Newsletter & Stay Updated
